Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oxford BioDynamicsOXBOF 3-Year EBITDA Growth Rate is 51.70% as of Mar. 2026. The stock has 4 warning signs investors should review. Among 165 Medical Diagnostics & Research companies, Oxford BioDynamics ranks better than 86.06% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 51.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 27.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -2.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Oxford BioDynamics was 51.70% per year. The lowest was -42.20% per year. And the median was -7.25% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Oxford BioDynamics 3-Year EBITDA Growth Rate Related Terms
OXBOF vs TMO, DHR, IDXX: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Oxford BioDynamics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford BioDynamics 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Oxford BioDynamics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Oxford BioDynamics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 51.70% mean?
Oxford BioDynamics (OXBOF) has a 3-Year EBITDA Growth Rate of 51.70% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Oxford BioDynamics and its competitors. According to the industry distribution chart, Oxford BioDynamics ranks #23 out of 165 companies in the Medical Diagnostics & Research industry, placing it in the top 13.9%.
Is Oxford BioDynamics' 3-Year EBITDA Growth Rate too high?
Oxford BioDynamics' current 3-Year EBITDA Growth Rate is 51.70%. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 11.50. Oxford BioDynamics' value of 51.70% is 349.6% above this industry median. Based on the distribution chart, Oxford BioDynamics ranks #23 out of 165 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Oxford BioDynamics' 3-Year EBITDA Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Oxford BioDynamics ranks #23 out of 165 companies for 3-Year EBITDA Growth Rate. This places Oxford BioDynamics in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 11.50. Oxford BioDynamics' value of 51.70% is 349.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.50, based on 165 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oxford BioDynamics's current 3-Year EBITDA Growth Rate of 51.70% is 349.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Oxford BioDynamics and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oxford BioDynamics's current 3-Year EBITDA Growth Rate is 51.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioDynamics stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioDynamics (OXBOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.01, compared to a current price of $0.00 — trading 85% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 51.70% and 349.6% above the Medical Diagnostics & Research industry median of 11.50. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Oxford BioDynamics (OXBOF), the current 3-Year EBITDA Growth Rate is 51.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oxford BioDynamics PLC is a biotechnology company focused on advancing personalized healthcare through the development and commercialization of precision medicine tests for serious and impactful diseases. The company is engaged in the commercialisation of proprietary molecular diagnostics products and biomarker research and development. It has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. The company generates revenue from the sales of proprietary products and biomarker research and development. Geographically, it generates the maximum revenue from the USA.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OXBOF has been successfully added to your 
